SCHEMBL8466271

SCHEMBL8466271

OC1(c2ccc(OC(F)(F)F)cc2)CCC2(CC1)OCCO2

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 11/20 0.45
SLC6A3 Q01959 8/20 0.43
SLC6A2 P23975 1/20 0.40
CCR1 P32246 1/20 0.39
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
KCNH2 Q12809 2/20 0.36
CYP2D6 P10635 1/20 0.36
DRD2 P14416 1/20 0.36
DRD1 P21728 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
ICMT O60725 1/20 0.36
PIM1 P11309 1/20 0.35
PIM2 Q9P1W9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22816525 0.82 SLC6A4 (0.45) SLC6A4SLC6A3SLC6A2MMP1MMP2
SCHEMBL14403245 0.82 DRD2 (0.39) SLC6A4SLC6A3DRD2HRH3
SCHEMBL20267107 0.80 SLC6A4 (0.51) SLC6A4SLC6A3SLC6A2CCR1MEN1
SCHEMBL613806 0.80 POLB (0.51) MEN1KMT2A
SCHEMBL9036581 0.80 OPRL1 (0.46) SLC6A4SLC6A3SLC6A2CCR1DRD2
SCHEMBL22816524 0.78 MMP1 (0.41) SLC6A4SLC6A3SLC6A2MMP1MMP2
SCHEMBL22816520 0.78 MEN1 (0.48) SLC6A4SLC6A3SLC6A2MMP1MMP2
SCHEMBL612754 0.77 OPRM1 (0.43) SLC6A4SLC6A3SLC6A2DRD2DRD1
SCHEMBL5237277 0.76 DRD2 (0.54) SLC6A4SLC6A3SLC6A2CCR1MMP1
SCHEMBL12208869 0.76 POLB (0.36) SLC6A4SLC6A3MEN1KMT2AHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10882856-B2 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases BEIGENE, LTD. (KY) 2021-01-05 US disclosed
WO-2018054365-A1 NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BEIGENE, LTD. (KY) 2018-03-29 WO disclosed
EP-0675187-B1 Liquid crystalline compounds and liquid crystal composition CHISSO CORP (JP) 1999-09-15 EP disclosed
US-5670085-A Liquid crystalline compound and liquid crystal CHISSO CORPORATION (JP) 1997-09-23 US disclosed
US-5534187-A CONTAINING CYCLOHEXANE RING CHISSO CORPORATION (JP) 1996-07-09 US disclosed
EP-0675187-A2 Liquid crystalline compounds and liquid crystal composition Chisso Corporation (JP) 1995-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10882856-B2 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases IDO1, TPH1, IDO2 SLC6A4 159/4885SLC6A3 408/4885SLC6A2 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.